202 related articles for article (PubMed ID: 37626912)
1. Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy.
Ivanova MM; Dao J; Slayeh OA; Friedman A; Goker-Alpan O
Cells; 2023 Aug; 12(16):. PubMed ID: 37626912
[TBL] [Abstract][Full Text] [Related]
2. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
Lee MH; Choi EN; Jeon YJ; Jung SC
Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
[TBL] [Abstract][Full Text] [Related]
3. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
[TBL] [Abstract][Full Text] [Related]
4. Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy.
Saccheri MC; Cianciulli TF; Challapa Licidio W; Lax JA; Beck MA; Morita LA; Gagliardi JA;
Echocardiography; 2018 May; 35(5):643-650. PubMed ID: 29457264
[TBL] [Abstract][Full Text] [Related]
5. Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic.
Zemánek D; Januška J; Honěk T; Čurila K; Kubánek M; Šindelářová Š; Zahálková L; Klofáč P; Laštůvková E; Lichnerová E; Aiglová R; Lhotský J; Vondrák J; Dostálová G; Táborský M; Kasper D; Linhart A
ESC Heart Fail; 2022 Dec; 9(6):4160-4166. PubMed ID: 36087038
[TBL] [Abstract][Full Text] [Related]
6. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
[TBL] [Abstract][Full Text] [Related]
7. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy.
Li RK; Li G; Mickle DA; Weisel RD; Merante F; Luss H; Rao V; Christakis GT; Williams WG
Circulation; 1997 Aug; 96(3):874-81. PubMed ID: 9264495
[TBL] [Abstract][Full Text] [Related]
9. Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping.
Deborde E; Dubourg B; Bejar S; Brehin AC; Normant S; Michelin P; Dacher JN
Diagn Interv Imaging; 2020 Feb; 101(2):59-67. PubMed ID: 31519470
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
[TBL] [Abstract][Full Text] [Related]
11. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
12. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.
Weidemann F; Beer M; Kralewski M; Siwy J; Kampmann C
Mol Genet Metab; 2019 Feb; 126(2):169-182. PubMed ID: 30594474
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
[TBL] [Abstract][Full Text] [Related]
14. Increased Transforming Growth Factor-β Levels Associated With Cardiac Adverse Events in Hypertrophic Cardiomyopathy.
Ayça B; Sahin I; Kucuk SH; Akin F; Kafadar D; Avşar M; Avci II; Gungor B; Okuyan E; Dinckal MH
Clin Cardiol; 2015 Jun; 38(6):371-7. PubMed ID: 25973737
[TBL] [Abstract][Full Text] [Related]
15. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
16. Late-onset and classic phenotypes of Fabry disease in males with the
Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
[TBL] [Abstract][Full Text] [Related]
17. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
18. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
[TBL] [Abstract][Full Text] [Related]
19. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy?
Azevedo O; Marques N; Reis L; Cruz I; Craveiro N; Antunes H; Lourenço C; Gomes R; Guerreiro RA; Faria R; Sá F; Lima R; Gaspar P; Faria R; Miltenberger-Miltenyi G; Sousa N; Cunha D;
Am Heart J; 2020 Aug; 226():114-126. PubMed ID: 32531501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
